Podcast Episodes
Back to Search311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
STAT reporter Jason Mast joins us to discuss Anthony Fauci's memoir "On Call," which was published this week. Hosts Allison DeAngelis and Adam Feuers…
2 years, 4 months ago
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
STAT's Nicholas Florko joins to explain what it means to be a reporter writing about the commercial determinants of health. Hint: Florko's most recen…
2 years, 4 months ago
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics' meeting with an FDA advisory committee. We also discuss the latest news in th…
2 years, 4 months ago
308: An ASCO preview & another Duchenne trial failure
We preview some of the research that will be presented at The American Society of Clinical Oncology conference in Chicago. We also discuss the latest…
2 years, 4 months ago
307: More tumult at BIO & coercive care for sickle cell patients
This week on “The Readout LOUD,” STAT's Chief Washington Correspondent Rachel Cohrs Zhang joins us to discuss the layoffs at trade group BIO and how …
2 years, 5 months ago
306: Live! From the STAT Breakthrough Summit West
On this week’s "Readout LOUD," we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that no…
2 years, 5 months ago
305: Everything you need to know about H5N1 bird flu
This week on "The Readout LOUD," STAT senior infectious diseases reporter Helen Branswell walks us through ongoing H5N1 outbreak in the U.S. and issu…
2 years, 5 months ago
304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at …
2 years, 5 months ago
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. …
2 years, 6 months ago
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon?
We cover all that and more this week on “The Readout LOUD,” STAT’s b…
2 years, 6 months ago